Alx oncology and quantum leap healthcare collaborative™ announce the selection of evorpacept in the i-spy-p1 trial in combination with enhertu® in breast cancer

South san francisco, calif. , aug. 16, 2022 /prnewswire/ -- alx oncology holdings inc., ("alx oncology") (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, and quantum leap healthcare collaborative™ ("quantum leap") today announced that alx oncology's next generation cd47 blocker, evorpacept, has been selected for a new investigational treatment arm in the i-spy-p1 trial for the treatment of patients with unresectable or metastatic her2-positive and her2-low breast cancer.
ALXO Ratings Summary
ALXO Quant Ranking